Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Fineline Cube Jan 23, 2026
Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Fineline Cube Jan 23, 2026
Company Deals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

Fineline Cube Jan 23, 2026
Company Deals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

Fineline Cube Jan 23, 2026
Company Deals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Fineline Cube Jan 23, 2026
Company Drug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Fineline Cube Jan 23, 2026
Company Drug

Auzone Biological Technology Gets FDA Approval for Edaravone Oral Preparations in ALS

Fineline Cube Aug 22, 2023

Suzhou Auzone Biological Technology Co., Ltd. has received approval from the US Food and Drug...

Company

RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results

Fineline Cube Aug 22, 2023

China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first...

Company Drug

Gilead’s Magrolimab Phase III Trial for AML Faces Partial Hold by FDA

Fineline Cube Aug 22, 2023

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration (FDA) has imposed...

Company

Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion

Fineline Cube Aug 22, 2023

China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49%...

Company Drug

Pfizer’s RSV Vaccine Abrysvo Receives FDA Authorization for Maternal Immunization

Fineline Cube Aug 22, 2023

The US Food and Drug Administration (FDA) has authorized the use of Pfizer’s (NYSE: PFE)...

Company Drug

J&J’s Teclistamab Granted Priority Review in China for Relapsed Multiple Myeloma

Fineline Cube Aug 22, 2023

The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson’s (J&J, NYSE:...

Company

Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales

Fineline Cube Aug 22, 2023

China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38...

Company

New Horizon Health Ltd Reports 264.6% YOY Revenue Increase and First Recurring Profits

Fineline Cube Aug 22, 2023

China-based New Horizon Health Ltd (HKG: 6606), a leading cancer diagnostics developer, has released its...

Company Drug

Amgen’s Lumakras Faces Full Registration Review by FDA for KRAS-Mutated NSCLC

Fineline Cube Aug 22, 2023

The US Food and Drug Administration (FDA) is scheduled to review an application submitted by...

Company Drug

AstraZeneca’s Forxiga Demonstrates Clinical Benefits in Heart Failure and COPD Patients

Fineline Cube Aug 21, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced evidence that its SGLT2 inhibitor, Forxiga...

Policy / Regulatory

NHSA Releases Preliminary Review Results for National Reimbursement Drug List Adjustments

Fineline Cube Aug 21, 2023

The National Healthcare Security Administration (NHSA) has released a notification disclosing the drugs that have...

Company

Novartis Sets Tentative Date for Sandoz Spin-Off, Targets October 4

Fineline Cube Aug 21, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced October 4 of this year as the...

Company

Jiangsu Hengrui Pharmaceuticals Reports 9.19% YOY Revenue Growth in H1 2023 Financial Report

Fineline Cube Aug 21, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has released its financial report for the first...

Drug

AstraZeneca’s Forxiga Gains New Indication Approval in China for Chronic Heart Failure

Fineline Cube Aug 21, 2023

UK-based pharmaceutical major AstraZeneca plc (AZ, NASDAQ: AZN) has announced that China’s National Medical Products...

Company Deals

Hua Medicine Achieves Development Milestone for HuaTangNing with Bayer Agreement

Fineline Cube Aug 21, 2023

China-based Hua Medicine (HKG: 2552) has announced the achievement of a significant development milestone for...

Company Drug

MSD’s Welireg Meets Primary Endpoint in Phase III RCC Study but Misses OS Milestone

Fineline Cube Aug 21, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed that the ongoing Phase III study...

Company Deals

CARsgen Therapeutics Partners with Moderna to Combine CAR-T Therapy with mRNA Cancer Vaccine

Fineline Cube Aug 21, 2023

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a collaboration agreement with US mRNA...

Company Deals

Simcere Pharmaceutical Group Secures Exclusive Rights to CMAB009 in China

Fineline Cube Aug 21, 2023

Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced that its subsidiary, Jiangsu Simcere Zaiming Pharmaceutical...

Company Deals

Ezisurg Medical Partners partners with Vathin for Global Disposable Endoscope strategic partnership

Fineline Cube Aug 21, 2023

Ezisurg Medical Co., Ltd has announced a strategic partnership with Hunan Vathin Medical Instrument Co.,...

Company

Fosun Pharma Adjusts Investment Allocation for 2022 Non-Public Offering Projects

Fineline Cube Aug 21, 2023

Fosun Pharma (SHA: 600196) has declared adjustments to the investment amounts for some of its...

Posts pagination

1 … 433 434 435 … 613

Recent updates

  • Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services
  • Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials
  • PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline
  • J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
  • AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

Company Drug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

Company Deals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.